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Abstract: Acute lymphoblastic leukemia (ALL) treatment regimes are amongst the longest, most intensive and complex used in hemato-
oncology. Despite this, while treatment of pediatric ALL is a success story, we are far from being able to ensure a durable response in 
adult ALL. This is not due to failure of induction therapy as a complete remission (CR) is achieved in over 90% of patients. However 
the challenge remains in ensuring a sustained remission. Furthermore in the face of relapsed disease, salvage therapies currently offer a 
poor chance of a good outcome. This article reviews the novel agents which show the most promise in the treatment of adult ALL.
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Introduction
In  adult  acute  lymphoblastic  leukemia  (ALL)  the 
5 year overall survival (OS) has been estimated at 
35%–47%1–7 and while there have been recent age-
dependent  improvements  in  survival,8,9  5  year  OS 
in  adults  compares  poorly  with  that  in  childhood 
ALL where it has been estimated to be over 80%.10 
This is not due to failure of induction therapy as a 
  complete remission (CR) is achieved in over 90% of 
patients.1 However the challenge remains in ensuring 
a   sustained remission and in the design of effective 
salvage regimens.
The  understanding  of ALL  disease  biology  has 
grown and we are gaining more insight into the genetic 
and  pharmacogenetic  factors  associated  with  poor 
outcome. Additional therapeutic targets have become 
apparent and there is also better insight into how to 
use existing agents. This article outlines the current, 
emerging agents that show promise for improving the 
outcome of ALL treatment in adults.
Monoclonal Antibodies
Monoclonal  antibodies  have  specificity  for  sin-
gle  epitopes  and  have  found  increasing  uses  in 
  clinical medicine as both diagnostic tools as well as 
therapeutic agents.
Unmodified monoclonal antibodies
Rituximab
Rituximab has already had a considerable impact on 
the treatment of various B cell malignancies.11 This 
chimeric anti CD20 IgG monoclonal antibody induces 
antibody-dependent and complement mediated cyto-
toxicity as well as apoptosis. Its efficacy is well estab-
lished in B cell Non Hodgkin Lymphomas (NHL), 
particularly in combination with chemotherapy.12
Compared to mature B cells and their malignant 
counterparts, expression of CD20 is less commonly 
expressed on immature B cells and there is also a lower 
intensity of expression. While 80%–90% of Burkitt-
type ALL  cells  express  high  levels  of  CD20,  only 
40%–50% of precursor B-lineage ALL cells express 
this antigen and with varying intensity.13 It is, however, 
important to note that no data are available to corre-
late a threshold for antigen expression and response 
to  rituximab.  Particularly  intriguing  is  the  observa-
tion that CD20 expression increases following induc-
tion chemotherapy in pediatric patients and it has been 
  postulated that this immunophenotypic alteration could 
be exploited with increased CD20 expression correlat-
ing to enhanced rituximab cytotoxicity in vitro.14
Hoelzer  et  al  initially  reported  results  of  a 
chemoimmunotherapy regimen in Burkitts lymphoma 
(BL)  or  B  acute  lymphoblastic  leukemia  (B-ALL) 
in patients aged over 55. Twenty-six patients with 
B-ALL and a further 26 patients with mature B-ALL 
or  BL  received  chemotherapy  by  the  B-NHL2002 
protocol with the addition of rituximab. For patients 
with precursor B-ALL, CR rate was 63% with a 1 year 
OS of 54% and in the mature B-ALL/BL group CR 
was 81% with a 1.5 year OS of 84%. Though follow 
up was short, this compared favorably with historical 
controls.18
The MD Anderson group studied 76 patients with 
BL and B-ALL evaluating the outcome of the addition 
of rituximab to Hyper CVAD (fractionated cyclophos-
phamide,  vincristine,  doxorubicin,  dexamethasone 
plus methotrexate, high dose cytarabine). Rituximab 
was given at a dose of 375 mg/m2 intravenously (IV) 
on Days 1 and 11 of hyper CVAD and on Days 2 and 8 
of methotrexate and cytarabine. All but 4 patients had 
previously  untreated ALL.  Rituximab  addition  was 
not associated with increased therapy related toxicity. 
Overall, CR rates did not differ when rituximab was 
added but compared to historical controls, there was a 
significantly reduced relapse rate, an improved 3 year 
OS and complete remission duration (CRD), particu-
larly in the over 60 age group.15 An update on the same 
patient group also revealed improved long term out-
come with the addition of rituximab to therapy.19
An important point to bear in mind when evaluating 
these data is that neither of these two early studies 
were  able  to  ensure  that  comparisons  were  made 
between patients with CD20 positive B-ALL (defined 
as greater than 20% expression) and CD20 negative 
B-ALL  treated  with  rituximab  or  without.  Since 
studies have shown that that CD20 expression is an 
independent poor prognostic factor,20,21 this important 
source of potential bias needs to be taken into account 
when interpreting the data.
In the German Multicenter Study Group for Adult 
ALL (GMALL) study 07/2003, younger patients with 
CD20  positive  B-ALL  were  treated  with  rituximab 
according  to  risk  group.  In  the  standard  risk  group 
(  definition  of  risk  groups  summarized  by    Hoelzer 
et al)22 rituximab improved the CR rate (from 57% emerging therapies in adult acute lymphoblastic leukemia
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Therapy Hyper- 
cVAD
Hyper- 
cVAD +  
Ritux
GMALL  
07/2003  
(High risk)
GMALL  
07/2003 +  
Ritux  
(High risk)
GMALL  
07/2003 
(standard  
risk)
GMALL  
07/2003 +  
Ritux  
(standard  
risk)
Hyper- 
cVAD
Modified   
Hyper-  
cVAD +  
Ritux
Overall CR 85% 86% 40%∞ 75%∞ 93% 94% 94% 94%
Overall 3 yr CRD 66% 91% * * 48% 64% 40% 67%
Overall 3 year OS 53% 89% 32% 54% 54% 75% 45% 61%
Age .60 3year CRD 44% 100% – – – – 50% 45%
Age .60 3 yr OS 19% 89% – – – – 32% 28%
Age ,60 3 yr CRD 73% 88% – – – – 38% 70%
Age ,60 3 yr OS 70% 90% – – – – 47% 75%
notes: ∞Of the high risk patients who proceeded to SCT; *data not available; +not evaluated. where data is available, OR and CR rates of CD20+ve 
patients are included in table only.
Abbreviations: ALL, acute lymphoblastic leukemia; BL, Burkitts lymphoma; CR, complete remission; CRD, CR duration; GMALL, German Multicenter 
Study Group for Adult ALL; Hyper-CvAD, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone plus methotrexate, high dose 
cytarabine; OS, overall survival. 
Table 1. Studies comparing the efficacy of rituximab in adults with B-ALL.
Trial Thomas et al15 Hoelzer et al16 Thomas et al17
Diagnosis B-ALL/BL B-ALL B-ALL
evaluable patients 76 185 282
evaluable CD20 +ve patients + 185 150
Age 16–79 15–55 13–83
to 89%) as well as the 3 year OS (54% vs. 75%) and 
CRD (48% vs. 64%). Two thirds of patients in the high 
risk group proceeded to allogeneic stem cell transplant 
(SCT) and in this group rituximab was associated with 
an improved OS (40% vs. 75%).16
Another study from the MD Anderson included 
282 adults and adolescents who were treated with 
standard  or  modified  hyper  CVAD,  with  the  latter 
regimen incorporating anthracycline intensification, 
alteration  to  number  of  intrathecal  treatments  and 
extension of maintenance phase. If there was signifi-
cant CD20 expression (again, defined as over 20% 
expression),  rituximab  was  incorporated  into  the 
modified regimen.17 Median age was 41 years (range 
13 to 83) and 21% of the study cohort was older than 
60. CR was similar across the treatment groups, but 
in CD20 positive patients aged less than 60, the addi-
tion of rituximab to modified hyper CVAD resulted in 
an improved 3-year CRD (70% vs. 38%, P , 0.001) 
rate and OS (75% vs. 47%, P = 0.003) compared 
with  standard  hyper  CVAD.  In  contrast,  young 
patients  with  CD20  negative  B-ALL  did  not  have 
an improved outcome when treated with modified as 
opposed to standard hyper CVAD regimens (3-year 
CRD 72% with rituximab vs. 68% without, P = not 
significant). BL and B-ALL patients aged over 60 did 
not benefit from rituximab overall (3 year OS 28% 
with rituximab vs. 32% without P = not significant), 
which may relate to a higher rate of death in CR.17
These data (summarized in Table 1) indicate that 
rituximab decreases risk of relapse and is associated 
with little excess toxicity. Of course, physicians do 
need to maintain vigilant to the rare, rituximab asso-
ciated complications such as viral hepatitis reactiva-
tion and development of fatal progressive multifocal 
leucoencephalopathy  related  to  JC  polyomavirus. 
Two on-going phase 3 randomized controlled studies 
(UK National Cancer Research Institute UKALL14 
and the French Group for Research in Adult Acute 
Lymphoblastic Leukemia GRAALL2005 trial) will 
confirm or refute the benefit of this agent in ALL.
Other anti CD20 antibodies are now available and 
may have different characteristics. Ofatumumab, for 
example has greater affinity for CD20, Veltuzumab 
is a humanized anti CD20.23 These agents have been 
little studied in ALL to date.
Immunotoxin-Conjugated Antibodies
CD22 is a member of the sialic acid binding immu-
noglobulin-like lectin family of adhesion molecules 
and is expressed in virtually all malignant B cells. 
However,  while  the  anti  CD22  Epratuzumab  has Lee and Fielding
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shown limited clinical efficacy,24 this molecule is an 
attractive target for conjugation with immunotoxins 
as bound molecules are rapidly internalized.25
Combotox  is  a  mixture  of  two  immunotoxins 
prepared by coupling a ricin A chain to anti CD22 
and  CD19  antibodies.  Seventeen  patients  aged 
19–72 with refractory or relapsed ALL were given IV 
Combotox in a dose escalation regime. The maximum 
tolerated  dose  (MTD)  was  7  mg/m2  per  dose  or 
21 mg/m2 per cycle and vascular leak syndrome was 
the dose-limiting toxicity. Two patients developed 
reversible grade 3 elevations in liver function tests. 
The maximum plasma concentration (Cmax) and half 
life (t1/2) were both inversely proportional to blast 
count (Cmax ranged from 66 to 1451 ng/mL and t1/2 
from less than 4 to 9.9 hours in patients with a high 
and low blast count respectively). Rapid reductions 
in  blasts  suggested  specific  cytotoxicity.  One 
patient achieved partial remission and proceeded to 
allogeneic SCT.26
Furthermore, data from a phase 1 trial in children 
suggested disease reduction prior to combotox may 
improve its efficacy.27
The  MD  Anderson  have  reported  early  and 
promising  results  of  Inotuzumab  ozogamicin 
(IO),  a  CD22  monoclonal  antibody  attached  to 
calicheamycin.28  Forty  patients  aged  6  to  80  with 
relapsed or refractory ALL received 1.8 mg/m2 IV 
over 1 hour every 3 weeks and overall at the time 
of  reporting,  20  patients  (56%)  achieved  a  CR  or 
complete marrow response. Of these 20, 12 were able 
to proceed to SCT. The most significant side effect 
was liver function abnormalities that were reported 
in 25% and severe in 11%. Two of these patients had 
liver biopsies that revealed periportal fibrosis.
This high CR rate in a heavily pretreated group 
of patients is noteworthy as is the high number of 
patients  who  proceeded  to  transplant.  The  MD 
Anderson has since observed that in the year prior 
to the availability of IO, 38% of ALL beyond second 
remission were transplanted while after IO became 
available,  67%  were  transplanted.29  Between  June 
2010 and May 2011, 19 patients with a median age 
of 32 years (range 5–60) received an allogeneic SCT. 
With  a  median  follow  up  of  three  months  among 
surviving patients, a PFS of 59% at three months 
was observed.29
Bispecific antibodies
Blinatumomab
CD19 is a pan B cell antigen and is therefore an attrac-
tive therapeutic target. Blinatumomab is a bispecific 
T cell engaging antibody composed of a single chain 
variable fragment (scFv) against CD19 coupled to an 
scFv against CD3 with the aim of activating T cells 
bound to CD19 expressing ALL blasts, thereby induc-
ing perforin mediated death of the target cell. A phase 
2 clinical study of blinatumomab in 21 adult patients 
with  minimal  residual  disease  (MRD)  persistence 
or relapse has recently been reported.30 Each cycle 
involved a continuous IV infusion of Blinatumomab 
at 15 µg/m2/24 hours for 4 weeks, followed by a two-
week treatment free period. The most common side 
effect was lymphopenia (33.3%). A previous study in 
NHL used a higher dose of the drug and dose-limiting 
toxicity was neurological.31 At the lower dose used 
in this study, one patient experienced seizures and a 
further patient experienced syncope.
In terms of response, 16 subjects became MRD 
negative after one cycle of treatment; 12 of whom 
had been refractory to previous chemotherapy. This 
response was sustained in the majority of patients 
at a median follow up of 405 days. Eight patients 
progressed  to  allogeneic  SCT.  Of  the  4  relapses, 
2  were  in  isolated  extramedullary  sites  and  the 
other 2 patients relapsed with CD19 negative blasts. 
It  was  hypothesized  that  extramedullary  relapses 
occurred in immuneprivileged sites where T cells 
are   generally absent.30
Interim results from a GMALL study evaluating 
blinatumomab  in  adult  patients  with  relapsed  or 
refractory B-ALL have also been reported.32,33 The 
first 18 patients reported were aged 18 to 77 and also 
received this agent as a 4-week continuous infusion, 
of varying doses in subsequent weeks of treatment, 
followed  by  a  2-week  treatment  free  period  with 
responders eligible to receive a further 3 cycles. At 
the time of reporting, 12 patients had reached a CR 
within 2 cycles of treatment including 3 with t(4;11) 
and one patient with a Philadelphia positive (Ph+ve) 
B-ALL. Four responders proceeded to SCT. Overall, 3 
responders relapsed during treatment. One patient had 
a CD19 negative relapse post SCT. A further 2 patients 
relapsed  during  treatment  with  1  patient  having  a 
CD19 positive extramedullary relapse and the other a emerging therapies in adult acute lymphoblastic leukemia
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CD19 negative bone marrow relapse. While the most 
common side affect was fever and chills, 2 patients 
had severe side effects, which although reversible, 
necessitated  discontinuation  without  completion  of 
the first cycle. One of these patients had cytokine release 
syndrome (not seen in subsequent patients who were 
pretreated with dexamethasone or cyclophosphamide 
and a lower initial blinatumomab dose) and a second 
had encephalopathy and disorientation. Three further 
patients  had  reversible  neurological  events  that 
required a temporary interruption of treatment.33
As a result of these promising data a large regis-
tration study is now on-going in the European Union 
in patients with ALL who are MRD positive after 
3 cycles of therapy.
purine nucleoside Analogues
Purine  analogues  form  an  important  group  of 
cytotoxic  drugs  which  have  proven  efficacious  in 
hematological  malignancies.34  Three  novel  purine 
nucleoside  analogues  have  shown  promise  in  the 
treatment ALL.
Nelarabine
Nelarabine is a soluble nucleoside analogue that is 
converted to 9-β-D-arabinofuranosylguanine (ara-G) 
after demethoxylation by adenosine deaminase.  Ara-G, 
which is resistant to purine nucleoside phosphorylase 
(PNP)  mediated  phosphorylysis,  is  intracellularly 
triphosphorylated to the active nucleotide ara-GTP 
which  is  then  incorporated  into  DNA,  resulting 
in  chain  termination,  inhibition  of  ribonucleotide 
reductase  and  programmed  cell  death.40  Ara-GTP 
appears  to  preferentially  accumulate  in  malignant 
T cells and less so in B cells in which it also has a 
shorter  half-life,  explaining  its  efficacy  in  T  cell 
malignancies. Nelarabine achieved fast track approval 
by the FDA in October of 2005 for the treatment of 
patients with T acute lymphoblastic leukemia (T-ALL) 
and T lymphoblastic lymphoma (T-LBL) who have 
not responded to or have relapsed following treatment 
with at least two chemotherapeutic regimens. The use 
of nelarabine for T-ALL in adult patients has been 
studied in a number of trials, which are summarized 
in Table 2.
Kurtzberg et al studied dose escalations of nelara-
bine in multiple hematological malignancies in both 
adult  and  pediatric  patients  establishing  a  MTD 
of 40 mg/kg in adults. Of 13 evaluable adults with 
T-ALL/T-LBL, 15% achieved CR and 62% achieved 
PR. However, the drug was associated with significant 
neurotoxicity, which was mostly reversible including 
weakness, ataxia, and confusion. Coma was observed 
in 3 of 4 adults.35
A more focused CALGB 19801 study examined 
the outcome of using nelarabine only in relapsed or 
primary refractory T cell malignancies, primarily in 
adults. The dose used in this study was 1.5 g/m2 on 
days 1, 3 and 5, repeated in a 21-day cycle. Patients 
with  residual  disease  after  the  first  course  were 
offered a second and patients who achieved a CR 
after the first cycle were eligible to receive another 
two courses. Thirty-nine patients were evaluable and 
31% of T-ALL and a further 31% of T-LBL patients 
achieved a CR. This dosing schedule was also better 
tolerated with a markedly lower incidence of grade 
3 or 4 neurotoxicity compared with that reported in 
Kurtzberg et al.36
A  National  Cancer  Institute  phase  2  study  of 
nelarabine  in  Non-Hodgkins  Lymphoma  included 
Table 2. Trials of Nelarabine monotherapy in relapsed or refractory adult T-ALL/LBL.
Trial Kurtzberg et al35 DeAngelo et al36 Goy et al37 czuczman et al38 Gokbuget39
Total evaluable patients 93 39 17 19 126
evaluable adults  
with T-ALL/T-LBL
13 39 8 19 126
Diagnosis T-ALL/T-LBL T-ALL/T-LBL T-LBL cutaneous and  
peripheral T-LBL
T-ALL/ 
T-LBL
Age range 22–75 16–66 33–81 33–69 18–81
ALL/LBL CR 15.0% 30.8% 25.0% 0% 36%
ALL/LBL PR 62% 10.3% 25.0% 10.5% 10%
Abbreviations: ALL, acute lymphoblastic leukemia; CR, complete response; LBL, lymphoblastic lymphoma; PR, partial response.Lee and Fielding
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13 patients with T-LBL. Nelarabine was administered 
at a dose of 1.5 g/m2/day on days 1, 3 and 5 in a 28-day 
treatment cycle and up to 6 cycles were   administered. 
Only 17 of the 23 patients were evaluable and over-
all 12% and 38% of patients achieved a CR and par-
tial response (PR) respectively. Four of 8 evaluable 
patients with T-LBL responded (2 to CR and 2 to PR).37 
The CALGB 59901 trial further evaluated nelarabine 
in cutaneous and peripheral T-LBL. Of 19 evaluable 
patients only 2 achieved a PR and none a CR. These 
poor results may reflect varying histological subtypes 
of the disease or varying disease biology compared to 
the other studies.38
The largest trial so far of nelarabine monotherapy 
in  the  setting  of  relapsed  or  refractory  T-ALL  or 
T-LBL in adults is the recently published GMALL 
exploratory phase 2 study.39 The aim was to evaluate 
efficacy  and  tolerability  of  nelarabine  in  adult 
patients and the feasibility of subsequent SCT. One 
hundred and thirty-three patients aged 18–81 were 
recruited  and  administered  nelarabine  using  the 
CALGB dosing regime. Study treatment was stopped 
in those who had not achieved a CR after two cycles 
and patients in CR, eligible for a SCT, and with an 
available  donor  were  removed  from  the  protocol. 
Overall,  after  2  cycles,  36%  and  10%  of  patients 
achieved a CR and PR respectively. A small number 
of patients had a third cycle and no additional CRs 
were obtained from this extra treatment. Interestingly, 
13 patients entered the study a second time in relapse 
(including 8 after SCT) and 5 of these achieved a 
CR after 1–2 cycles. Myeloid blasts were associated 
with 5 patients that didn’t respond in this group. Of 
particular relevance in interpreting the results of other 
trials, none of the patients with the initial diagnosis of 
T-LBL achieved a CR.
Despite  the  heavy  pretreatment  of  this  cohort, 
toxicity  was  low  with  overall  16%  neurotoxicity 
and  7%  grade  3–4  toxicity.  There  was  also  an 
acceptable level of grade 3–4 neutropenia (37%) and 
thrombocytopenia (17%).
In  this  GMALL  study,  80%  of  the  45  patients 
who  achieved  a  CR  from  nelarabine  monotherapy 
  proceeded to SCT. Three year OS in this transplanted 
group was 36% compared to 0% in those achieving 
CR with nelarabine but not receiving SCT.39
Further  work  is  needed  to  determine  the 
  optimal use of nelarabine in order to maximize its 
antileukemic affect while minimizing toxicity. This 
is likely to involve incorporation of nelarabine into 
combination regimens and broadening its indication 
beyond relapse. There is a recently published study of 
7 children with relapsed or refractory T cell leukemia 
or  lymphoma  who  were  treated  with  nelarabine, 
etoposide  and  cyclophosphamide.  All  subjects 
achieved a response including a CR in all 4 patients 
with T-ALL and the one patient with bilineage ALL/
acute myeloid leukemia (AML).41
The ongoing UKALL14 and forthcoming GMALL 
08/2011 studies will both look at the role of nelara-
bine at induction, in UKALL14 administration will 
be randomized.
Clofarabine
Clofarabine  is  another  nucleoside  purine  analogue 
with similarities to other drugs of this class as well 
as some unique qualities. It is phosphorylated in the 
intracellular compartment to its active triphosphate 
form  and  combines  the  fludarabine-like  ability  of 
inhibiting DNA polymerase by terminal incorporation 
into DNA and the cladribine-like quality of inhibiting 
ribonucleotide reductase.47 Clofarabine is also resis-
tant to PNP and adenosine deaminase and appears to 
directly affect the mitochondrial membrane leading 
to release of apoptosis inducing factors.48
A significant body of evidence supports its use in 
chronic lymphocytic leukemia (CLL) and AML and 
it is also licensed for use in relapsed and refractory 
pediatric ALL who have had two previous lines of 
therapy.49–51 However, the evidence for clofarabine, 
summarized in Table 3, in adult ALL is more limited.
Kantarjian  and  colleagues  explored  Clofarabine 
monotherapy in a phase 1 followed by a phase 2 trial 
and although the number of ALL patients were small, 
there  was  a  limited  response.42,43  Clofarabine  was 
administered as an hour-long intravenous infusion daily 
for 5 consecutive days and the MTD in acute leukemia 
was 40 mg/m2 per infusion. The most common grade 
3–4 side effect was hepatotoxicity. Eighty-one percent 
of patients developed febrile neutropenia and 50% had 
documented infection during treatment. There were 
no deaths directly related to drug toxicity. Two of the 
12 patients with ALL had a CR.
Studies have examined combinations of clofarabine 
in conjunction with cyclophosphamide and cytarabine 
in  adult ALL.  Cyclophosphamide  is  an  alkylating emerging therapies in adult acute lymphoblastic leukemia
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agent that mediates interstrand crosslinking of DNA 
and CLL cells have the capability of repairing this 
in vitro. Pretreatment of CLL cells with clofarabine 
interferes  with  this  capability  therefore  increasing 
apoptosis.52  Following  this  preclinical  data,  the 
treatment schedule designed for a phase 1 clinical 
trial  concerning  this  particular  chemotherapy 
combination  was  clofarabine  (at  10  or  20  mg/m2) 
on days 1, 3, 8, 10 administered two hours prior to 
cyclophosphamide (400 mg/m2). Of the 18 patients 
in this study, age ranged from 21 to 67 years with 
a median age of 51 and 6 had ALL. Four of these 
6 patients had adverse cytogenetics, and all patients 
in the study had refractory leukemia with multiple 
prior therapies. This chemotherapy combination did 
result in increased DNA damage and apoptosis but 
was,  however,  significantly  myelosuppressive  with 
a median time to marrow recovery of 45 days and 
one third of patients on the higher dose of clofarabine 
aplastic for over 60 days. Four patients died during 
therapy with 1 patient who had irreversible aplasia 
without recurrent leukemia at day 100 and multiorgan 
failure. Overall an impressive 50% of ALL patients 
achieved  CR  and  16.7%  a  PR,  but  none  of  these 
patients proceeded to SCT.45
In vitro data also indicated that clofarabine would 
increase  intracellular  cytarabine  concentrations 
thereby  augmenting  its  cytotoxicity.53  However,  in 
contrast  to  the  clofarabine  and  cyclophosphamide 
combination, clofarabine and cytarabine therapy did 
not result in a notable clinical benefit in the Southwest 
Oncology Group Study S0530 phase 2 trial. Thirty-
six patients with relapsed or refractory disease were 
included, induction therapy consisting of clofarabine 
40  mg/m2/day  and  cytarabine  1  g/m2/day  on  days 
1–5.  The  most  common  Grade  3  or  greater  non-
hematologic  toxicities  were  infection  (64%)  and 
metabolic  or  laboratory  abnormalities  (33%).  Ten 
deaths occurred during treatment, 7 of which were 
attributle to therapy. Only 17% achieved a CR, half 
of which also had incomplete count recovery.46
Future  work  will  define  optimal  combination 
therapies and dosing to maximize the antileukemic 
affect of clofarabine while minimizing its toxicity.
Forodesine
Forodesine, a PNP binding drug, has a unique mecha-
nism of action which does not depend on incorporation 
into DNA to exert its cytotoxic affects.54 Preclinical 
data indicate that forodesine is selectively cytotoxic 
to T-ALL cells.55
PNP is an enzyme that degrades deoxyguanosine 
(dGuo), which is continuously produced by the body 
as a by-product of DNA breakdown during cellular 
turnover. Inhibition of PNP results in accumulation of 
dGuo that is in turn phosphorylated to deoxyguanos-
ine triphosphate (dGTP). Intracellular accumulation 
of dGTP then results in cell cycle arrest and apoptosis 
via an ill-understood mechanism.56,57
A phase 1 study included 5 patients of whom 2 
patients had T-ALL in first relapse. Forodesine was 
administered intravenously over 30 minutes at a dose 
of 40 mg/m2 for five days (once on day 1 and then twice 
daily for the remaining 4 days). Cmax was achieved 
at the end of infusion, median t1/2 was 11 hours and 
the medication was mainly renally cleared. The most 
Table 3. Trials of clofarabine in relapsed or refractory adult ALL.
Trial Kantarjian42 
(monotherapy  
phase 1)
Kantarjian43 
(monotherapy  
phase 2)
Faderl et al44 
(+cytarabine)
Karp et al45  
(+cyclophosphamide)
Advani et al46  
(+cytarabine)
Total evaluable 
adults
51 62 32 18 36
Adults with ALL 13 12 2 6 36
Diagnosis ALL+ ALL+ ALL+ T-ALL (n = 1),  
ph+ve ALL (n = 1),  
B-ALL (n = 6)
B-ALL 
(80.6%)/ 
T-ALL (19.4%)
Age range 19–78 19–82 18–84 27–67 20–68
ALL CR 7.7% 16.6% 0% 50.0% 16.7%
ALL PR 7.7% 0% 0% 16.7% 0%
note: +No further diagnostic detail provided.
Abbreviations: ALL, acute lymphoblastic leukemia; CR, complete response; Ph+ve, Philadelphia positive; PR, partial response.Lee and Fielding
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common side affect was grade 3–4 neutropenia. Both 
patients had a transient improvement in blast count 
but there was no objective response in either.58
Further study is needed to determine the potential 
beneficial therapeutic effect of forodesine in ALL.
nOTcH 1 Inhibitors
NOTCH  receptors  play  a  key  role  in  mediating 
multiple stages of T cell development. This molecule 
consists of an extramembrane portion that attaches to 
activating ligands, resulting in proteolytic cleavage of 
the receptor complex that then releases an intracellular 
domain  to  translocate  into  the  nucleus  and  induce 
expression of NOTCH 1 target genes.59
The  first  link  between  NOTCH1  and  T-ALL 
was  the  demonstration  that  the  t(7;9)(q34;q34.3) 
translocation  resulted  in  a  truncated  NOTCH1 
receptor. This receptor was either more vulnerable 
to proteolytic cleavage and thus activation, or lacked 
a transmembrane portion to anchor the intracellular 
domain resulting in constitutive gene activation.60,61 
It  was  soon  discovered  NOTCH1  mutations  were 
not isolated to this particular translocation but that 
over  50%  of  human  T-ALL  samples  have  one  of 
a  variety  of  mutations  to  the  regulatory  portion, 
causing  ligand  independent  receptor  activation  or 
ligand hypersensitivity.62 This discovery established 
NOTCH1 as a potential therapeutic target.
One of the two key activating proteolytic steps 
which  cleaves  the  NOTCH1  molecule  on  ligand 
binding to release the intracellular domain involves 
the enzyme γ-secretase. This same enzyme is also 
involved  in  the  pathogenic  deposition  of  amyloid 
fibrils in the brain found in patients with Alzheimer’s 
disease.  Hence,  γ-secretase  inhibitors  (GSI),  origi-
nally  designed  for Alzheimer’s  therapy  have  been 
studied in T-ALL.
Preclinical models were promising with inhibition 
of  the  NOTCH1  receptor  by  GSIs  resulting  in 
decreased growth and proliferation characterized by 
G0/G1 cell cycle arrest.61,62 However a phase 1 trial 
of  the  GSI  MK-0752  in  patients  with T-ALL  was 
less encouraging. Six adult and 2 pediatric patients 
with  leukemia  (7  with  T-ALL  and  1  with  AML) 
received MK-0752 orally once a day at 150, 225, and 
300 mg/m2. Only 1 patient achieved a transient clinical 
response but with significant gastrointestinal toxicity.63 
Intestinal  endothelium  seems  to  be  particularly 
sensitive to NOTCH inhibition with an accumulation 
of mucus secreting goblet cells with GSIs. In addition, 
where GSIs appear to induce a significant response 
with  marked  apoptosis  in  murine  ALL  cell  lines, 
this is not reflected in human ALL cell lines where 
only a cytostatic affect is seen.61,62,64 Furthermore, as 
NOTCH1 receptor stimulation promotes cell growth 
via numerous mechanisms, additional mutations in 
any of these downstream pathways would conceivably 
ameliorate NOTCH1 inhibition and it is therefore not 
surprising that resistance to GSIs is prevalent.62
Few of our current standard cytotoxic therapies 
are used in isolation and there is early evidence that 
targeting both NOTCH1 activation as well as critical 
downstream steps can have a powerful antileukemic 
affect.  Concurrent  inhibition  of  AKT,65  Hedgehog 
and  Wnt,66  cyclin  D  kinase,67  PI3K-AKT-mTOR 
pathway65,68  need  more  investigation.  In  addition, 
study  of  a  glucocorticoid  resistant  ALL  cell  line 
showed that, in combination, GSIs and glucocorti-
coid induces apoptotic cell death and has the added 
positive affect of protecting mice from the gastroin-
testinal toxicity typical of GSIs.69
mTOR Inhibitors
The mammalian target of rapamycin (mTOR) is a 
serine/threonine kinase that, through its interactions 
with a number of signaling pathways, functions as a 
key regulator of cell growth, protein synthesis and cell 
cycle  pathways.  Many  hematological  malignancies 
have  aberrant  expression  of  mTOR  and  in  vitro 
as well as in vivo murine studies have shown that 
mTOR  inhibitors  (MTIs)  (sirolimus,  temsirolimus, 
everolimus) have activity against both B- and T-ALL 
cells.70 MTIs are widely used for immunosuppression 
and are relatively well tolerated.
Two phase 1/2 trials have investigated MTIs in 
the  setting  of  relapsed  hematological  malignan-
cies in adults which included two patients with ALL 
who  tolerated  therapy  but  without  any  objective 
response.71,72
Resistance to MTIs may occur by up-regulation 
of  other  intermediary  signals  in  the  PI3K/AKT/
mTOR signaling pathways. Combinations of inhib-
itors or combination of MTIs with chemotherapy 
or  steroids  have  been  explored  in  pre-clinical 
work  and  need  further  study  to  determine  their 
therapeutic value.73–79emerging therapies in adult acute lymphoblastic leukemia
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sorafenib
Sorafenib, a multi-targeted tyrosine kinase inhibitor 
with activity against RAF kinase, VEGF receptors, 
both wild type and internal tandem repeat mutated 
FLT3,  PDGF  receptors,  c-KIT,  and  RET  kinase80 
is  licensed  for  the  treatment  of  renal  cell  and 
hepatocellular carcinoma and is being evaluated in 
numerous malignancies.81–84
Preclinical work in B- and T-ALL cells suggest 
that sorafenib induces cell cycle arrest by directly 
inhibiting Erk, mTOR and Akt, and induces apoptosis 
by  cleavage  of  caspases  3,  7  and  PARP.85  Two 
patients with ALL were treated with sorafenib in a 
dose escalation manner in a phase 1 trial of relapsed 
or refractory leukemia.86 In this study the maximum 
tolerated dose was 400 mg BD orally for 21 days. 
At this dose 48% of patients experienced grade 3–4 
toxicity  overall  (most  common  20%  experienced 
fatigue  and  14%  febrile  neutropenia).  One  of  the 
2 ALL  patients  cleared  their  peripheral  blasts  and 
achieved  a  near  50%  reduction  in  marrow  blasts 
after 2 cycles. The authors note that this patient had 
a  mixed  lineage  leukemia  (MLL)  rearrangement 
with translocation (4;11), which has been associated 
with over expression of wild type FLT3 and in vitro 
sensitivity to FLT3 inhibitors.86
Aurora kinase Inhibitors
Three subtypes of Aurora kinases (A, B and C) make 
up  a  family  of  highly  conserved  serine-threonine 
protein kinases that have a key role in several stages 
of  mitosis.  Mutations  in  Aurora  kinases  resulting 
in their over expression or amplification have been 
observed in a wide range of malignancies.87 Aurora 
kinase inhibitors (AKI) attach to the ATP binding site, 
vary in their specificity for these target enzymes and 
most AKIs also have the capability of multi-kinase 
inhibition against ABL, JAK2 and FLT3. Their abil-
ity to inhibit ABL have made AKIs attractive agents 
for Ph+ve leukemias and it has also been observed 
that many AKIs can overcome resistance to tyrosine 
kinase inhibitors (TKI), even when arising from the 
T315I mutation.88
One of the first AKIs to be investigated in Ph+ve 
leukemia  was  MK−0457.  Initially  3  adult  patients 
with  T315I  mutated  chronic  myeloid  leukemia 
(CML,  2  patients)  and  ALL  (1  patient,  relapsed 
ALL,  aged  63)  were  administered  MK-0457  in  a 
  continuous infusion for 5 days at 2–3 week intervals. 
  Significant  BCR-ABL  inhibition  occurred  at  doses 
of 20 mg/m2/hour. The only reported side affect was 
reversible  pancytopenia.89  This  was  followed  by  a 
phase 2 trial which was closed early following the 
discovery of QTc prolongation in one subject.90
A  second AKI, AT9283,  has  pan-Aurora, ABL, 
FLT3 and JAK2 kinase inhibitor activity. In a phase 
1 trial which included patients with ALL, there was 
response  reported  in  patients  with AML  and  CML 
only.91  XL228  is  a  multi  kinase  inhibitor  and  is 
  currently the subject of a phase 1 trial of 27 patients 
with CML or Ph+ve ALL who have been either resis-
tant  or  intolerant  of  two  TKIs  or  have  the  T315I 
mutation. XL228 was administered in 1 hourly infu-
sions once or twice a week and the main side effect 
observed was increased insulin and glucose levels. An 
initial report has described clinical activity in 17 of a 
total 27 patients, evidenced by improvement in white 
cell or platelet count or greater than 1 log reduction in 
BCR-ABL levels, at doses of 3.6 mg/kg and higher. 
Seven of the 17 responders have the T315I mutation.92 
A fourth agent, Danusertib has pan-Aurora and ABL 
inhibitory activity and is in a phase 1 trial of 23 patients 
with relapsed CML or ALL. There are 11 patients with 
ALL included in the study and patients are adminis-
tered 3 hourly IV infusions for 7 days every 2 weeks 
in a dose-escalating regime. An early report from this 
study has described response in 6 patients.93
There  is  also  a  growing  body  of  preclinical 
  evidence that AKIs also have increased cytotoxicity 
when used in combination with TKIs, conventional 
chemotherapeutic drugs or other novel agents such as 
histone deacetylase inhibitors.94–97
The multi kinase inhibitory ability of AKIs has 
the  theoretical  advantage  of  greater  cytotoxicity 
and also decreased risk of leukemic cells   evolving 
resistance.  However,  we  are  yet  to  elucidate  the 
key biological   targets in Ph+ve ALL which mediate 
  clinical response.98 Until we do understand this, we 
are unlikely to design optimal treatment regimes and 
drug combinations that maximize the antileukemic 
affect while minimizing the toxicity of AKIs.
Histone Deacetylase Inhibitors  
and Hypomethylating Agents
Malignant  phenotype  is  not  determined  by  geno-
type  alone.  ‘Epigenetic’  modifications  influence Lee and Fielding
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gene function without altering the underlying DNA 
sequence.99 As an example, aberrant methylation of 
cytosine residues, particularly in and around so-called 
CpG islands can result in silencing of particular gene 
sequences including tumor suppressor genes and pro-
mote  tumor  formation.100  Epigenetic  modifications 
are common in ALL, and increased gene methylation 
has been associated with relapse and poorer progno-
sis.101,102 Such modifications may also play a role in 
ALL pathogenesis. For example, MLL mutated ALL 
can result in a translocation to produce the MLL-AF4 
protein  that  recruits  the  histone  methyltransferase 
DOT1L.  This  enzyme  methylates  the  histone  H3 
lysine 79 (H3K79) and accordingly there is reduced 
expression  of  several  critical  genes  that  have  this 
altered histone.103 A second epigenetic modification 
seen in ALL is hypermethylation. In infants, it has 
been demonstrated that one of the domains required to 
produce an MLL oncoprotein with leukemic potential 
is a sequence with homology to the regulatory por-
tion of eukaryotic DNA methyltransferase (DNMT1) 
(termed the MT domain). MLL MT recognizes the 
unmethylated  CpG  nucleotide  sequences  thereby 
silencing gene expression.104
Histone deacetylase inhibitors (HDACi) are able 
to modify chromatin structure and enhance DNA tran-
scription. While a significant body of preclinical data 
have shown HDACis to be cytotoxic to ALL cells,105 
a number of phase 1 trials of HDACis in adult leu-
kemic patients have included only small numbers of 
patients with ALL and it has not yet been determined 
if this class of drug will be useful in the treatment of 
this disease. A phase 1 study of LBH589 included 1 
patient with ALL106 and a phase 1 study of vorinostat 
included 2 patients with ALL.107
It has also been hypothesized that the ability of 
HDACis to open the chromatin configuration could 
allow  better  DNA  access  to  cytotoxics  as  well  as 
up-regulating DNA topoisomerase interaction thereby 
sensitizing leukemia cells to anthracyclines.108 Hence, 
most  of  the  ongoing  clinical  trials  of  HDACis  in 
ALL consist of this class of drug in a combination 
regime. Mummery et al have extensively reviewed 
the epigenetic abnormalities and the currently studied 
HDACis in relation to ALL.105
There has also been interest in hypomethylating 
agents.  In  vitro,  decitabine  has  significant  activity 
against ALL derived cell lines.109 A phase 1 study has 
been reported involving 39 patients (aged 4–67) with 
relapsed disease who were treated with an escalating 
dose  of  decitabine  alone  followed  by  decitabine 
combined with hyper CVAD in those who either did 
not respond or who lost their response to the single 
agent.110 Twenty-three percent of patients achieved a 
transient CR with decitabine alone and the optimal 
dose was determined to be 60 mg/m2 IV daily for 
5 days every fortnight. Half of patients who were 
treated  initially  with  decitabine  alone  were  then 
treated with hyper-CVAD as well. Fifty-two percent 
of patients achieved a response with this combination 
for a median duration of 4 months. The optimal dose 
when used in combination was 40 mg/m2 IV given 
for 5 consecutive days with each hyper CVAD cycle. 
The  authors  reported  no  significant  toxicity  with 
decitabine used alone or in combination. While these 
results may show some promise, the responses do 
seem short lived. We await further data of this class of 
agents in the treatment of ALL, with particular interest 
in whether decitabine facilitates patients proceeding 
to SCT and if other combination regimes can impact 
long term survival.
Mitoxantrone
Mitoxantrone is a type II topoisomerase inhibitor, 
has a favorable chemosensitivity profile in relapsed 
ALL and has a reported B cell specific affect.111,112 
In the ALL R3 trial, 239 pediatric patients in first 
relapse aged 1–18 were randomized to have either 
mitoxantrone  or  idarubicin  at  induction.  The 
randomization  was  terminated  early  by  the  Data 
and  Safety  Monitoring  Committee  because  there 
was  a  clear  improvement  in  relapse  rate  in  the 
mitoxantrone arm. Three year OS was 45.2% in the 
idarubicin group and 69% in the mitoxantrone group 
with  a  similar  improvement  to  3-year  progression 
free survival (36% to 65%). This improvement was 
achieved even though the overall toxic affects were 
lower in the mitoxantrone group, though there was a 
noted increased incidence of hematological toxicity 
in the later phases of treatment.113
So far, mainly clinical studies in adult ALL patients 
have  been  detailed  in  this  article.  However  in  the 
ALL R3 trial, mitoxantrone translated into a survival 
advantage of over 20% in this pediatric cohort, which 
is one of the most significant improvements to out-
come following a single modification of treatment. emerging therapies in adult acute lymphoblastic leukemia
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Similar work in adult ALL is required to determine if 
mitoxantrone is also beneficial in an older age group.
conclusion
There have been significant clinical responses to a 
number  of  novel  agents  (summarized  in  Table  4). 
Notably, nelarabine in T-ALL, as well as rituximab 
and blinatumomab in B-ALL are promising and are 
undergoing large international phase 2 and 3 studies 
in earlier phases of the disease. By contrast, consider-
ably more clinical study is required to determine what 
role these as well as immunotoxins, AKIs, HDACis, 
hypomethylating agents, GSIs, MTIs, mitoxantrone 
and other purine nucleoside analogues have in the 
treatment of adult ALL. It is important to be mind-
ful that although our attention is often optimistically 
directed towards new drugs, improved responses have 
been recently achieved with conventional and easily 
accessible agents whose use is established in other 
malignancies (eg, mitoxantrone and rituximab).
Furthermore, the majority of agents will unlikely 
realize their optimal clinical potential as monotherapy 
and an increasing knowledge of disease biology as 
well as an understanding of the mechanisms by which 
these agents exert their antileukemic affect will enable 
treatment regimes to be rationalized. Given the com-
plexity of this task, this can only be achieved with 
international collaboration.
In contrast to the previously practiced ‘one size 
fits all’ approach, current treatment principles are pro-
gressively more individualized with early risk strati-
fication and targeted therapy. As accurate assessment 
of  individual  risk  becomes  increasingly  possible, 
the therapeutic landscape may change considerably. 
It will therefore be important that our study designs 
recognize this and incorporate novel end points such 
as MRD quantification as well as high quality cor-
relative science projects.
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